These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26558417)

  • 1. Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
    Abdel-Rahman O; Ahmed H; ElHalawani H
    Expert Rev Respir Med; 2016 Feb; 10(2):223-34. PubMed ID: 26558417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
    Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Expert Opin Drug Saf; 2015 Oct; 14(10):1507-18. PubMed ID: 26394770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
    Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L
    Clin Lung Cancer; 2017 Sep; 18(5):e333-e340. PubMed ID: 28462807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
    Abdel-Rahman O; Elhalawani H
    Future Oncol; 2015; 11(7):1109-22. PubMed ID: 25804125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
    Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
    Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
    Rossi A; La Salvia A; Di Maio M
    Expert Rev Respir Med; 2017 Mar; 11(3):171-180. PubMed ID: 28152323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
    Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
    Amin Z; Jayalie VF; Rajabto W
    Acta Med Indones; 2017 Jan; 49(1):79-88. PubMed ID: 28450659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.